Nektar Therapeutics Starts Clinical Study

Nektar Therapeutics said it has begun dosing in a phase 1 clinical study evaluating NKTR-358, the company’s new biologic therapy, which is being developed to treat a wide range of auto-immune diseases and inflammatory disorders.

NKTR-358 selectively stimulates the growth and activation of regulatory T cells in the body in order to restore the body’s self-tolerance mechanisms. The study will evaluate single-ascending doses of NKTR-358 in approximately 50 healthy subjects.

By Stephen Holmes